報價延遲最少15分鐘:2025/06/28 11:18 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
128.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.51/0.62
|
|
企業價值
8.69B
|
| 資產負債 |
|
每股賬面淨值
5.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
249.38M
|
|
每股收益
3.35
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/28 11:18 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patientsliving with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe. |